ArticleClinical medicine insights. Endocrinology and diabetes2012
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
Article in Clinical medicine insights. Endocrinology and diabetes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study.World journal of diabetes · 2025Trial
- Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.Diabetes, obesity & metabolism · 2022Trial
- Insulin icodec: A novel once-weekly formulation for the treatment of type 1 and type 2 diabetes mellitus.Reviews in endocrine & metabolic disorders · 2025Review
- An update of contemporary insulin therapy.Journal of diabetes investigation · 2024Article
- Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.Current diabetes reviews · 2023Review
- Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis.Metabolites · 2021Article
- Facile synthesis of insulin fusion derivatives through sortase A ligation.Acta pharmaceutica Sinica. B · 2021Article
- Factors Influencing Insulin Absorption Around Exercise in Type 1 Diabetes.Frontiers in endocrinology · 2020Review
- Pharmacologic treatment options for type 1 diabetes: what's new?Expert review of clinical pharmacology · 2019Review
- Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.Annals of translational medicine · 2018Article
- Insulin analogs and cancer: a note of caution.Frontiers in endocrinology · 2014Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared to its rival basal insulin analogs, a longer duration of action and lower incidence of hypoglycemic events in both type 1 and type 2 diabetic patients has been demonstrated.1,2 Its unique mechanism of action is based on multihexamer formation after subcutaneous injection. This reportedly allows for less pharmacodynamic variability and within-subject variability than currently available insulin analogs, and a duration of action that is over 24 hours.3 The lack of proof of carcinogenicity with insulin degludec is yet another factor that would be taken into consideration when choosing the optimal basal insulin for a diabetic individual.4 A formulation of insulin degludec with insulin aspart, Insulin degludec 70%/aspart 30%, may permit improved flexibly of dosing without compromising glycemic control or safety.5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.